11:46 Thu 28 Sep 2017
Ergomed plc - Result of Placing
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN, IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO
Result of Placing
A total of 1,757,576 new ordinary shares in the Company of 1p each (the "Placing Shares") have been conditionally placed at a price of 165p per Placing Share (the "Placing Price"), raising proceeds of
The Placing Shares to be issued represent approximately 4.3% of the Company's existing issued ordinary share capital. The Placing Price represents a discount of approximately 4.1% to the Company's last 30 trading days volume weighted average price.
Director participation
The participation of Directors of
Director |
Interest in Ordinary Shares |
Aggregate value of Ordinary Shares to be acquired (£) |
Number of Ordinary Shares to be acquired |
Interest in Ordinary Shares following the Placing |
Resulting holding of Ordinary Shares as % of enlarged issued share capital |
|
231,250 |
74,250.00 |
45,000 |
276,250 |
0.65% |
Admission
Application has been made to the
Total voting rights
Following Admission the number of ordinary shares of 1 penny each in the capital of the Company in issue and number of voting rights will be 42,680,813. The above figure may be used by Shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
a) |
|
|
|
2 |
Reason for the notification |
||
a) |
Position/status |
Chairman |
|
b) |
Initial notification /Amendment |
Initial Notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
a) |
|
|
|
b) |
Legal Entity Identifier |
213800BVS8I9VMC1AP84 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
a) |
Description of the financial instrument, type of instrument
Identification code |
Ordinary shares of
GB00BN7ZCY67 |
|
b) |
Nature of the transaction |
Purchase of shares |
|
c) |
Currency |
GBP |
|
d) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
165p |
45,000 |
||
|
|||
e) |
Aggregated information - Aggregated volume - Price - Aggregated total |
45,000 165p |
|
f) |
Date of the transaction |
|
|
g) |
Place of the transaction |
|
Enquiries:
|
Tel: +44 (0) 1483 503205 |
|
|
|
|
|
|
|
|
|
|
|
Tel: +44 (0) 20 7260 1000 |
|
|
|
|
|
|
|
|
|
|
N+1 Singer |
Tel: +44 (0) 20 7496 3000 |
|
|
|
|
|
|
|
|
Tel: +44 (0) 20 3709 5700 |
|
|
||
|
|
|
MC Services - for Continental European enquiries |
Tel: +49 211 5292 5222 |
|
|
|
|
About
About PSR
PSR, established in 1998, is a full service specialist orphan drug CRO and recognised as a leading expert in the rare disease niche. PSR specialises in running complex orphan drug development programs requiring innovative regulatory and clinical approaches as well as pricing and reimbursement strategies. Besides outsourced project solutions, PSR provides insourced staffing solutions (orphan drug teams), temporary & permanent staffing, interim management solutions as well as training / coaching career programs.
PSR's dedication to the rare disease landscape is exemplified by an extensive track record of orphan drug projects in a wide range of therapeutic areas, its continued efforts to achieve true patient centricity and its societal commitments by participation in fundraising activities and public-private partnerships. For further information, visit: http://www.psr-group.com.
This announcement contains inside information which is disclosed in accordance with the Market Abuse Regulation.
Each of
This Announcement includes statements, estimates, opinions and projections with respect to anticipated future performance of the Company or future events ("forward-looking statements") which reflect various assumptions concerning anticipated results or events which may or may not prove to be correct. These forward looking statements can be identified by the use of forward looking terminology, including the terms "anticipates", "target", "believes", "estimates", "expects", "intends", "may", "plans", "projects", "should" or "will", or, in each case, their negative or other variations or comparable terminology or by discussions of strategy, plans, objectives, goals, future events or intentions. Such forward-looking statements reflect current expectations based on the current business plan and various other assumptions and involve significant risks and uncertainties and should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether or not such results will be achieved. As a result, prospective investors should not rely on such forward-looking statements due to the inherent uncertainty therein. No representation or warranty is given as to the completeness or accuracy of the forward-looking statements contained in this Announcement. Forward-looking statements speak only as of the date of such statements and, except as required by the
The distribution of this Announcement and the offering of the Placing Shares in certain jurisdictions may be restricted by law. No action has been taken by the Company or the Bookrunners that would permit an offering of the Placing Shares or possession or distribution of this Announcement or any other offering or publicity material relating to the Placing Shares in any jurisdiction where action for that purpose is required. Persons into whose possession this Announcement comes are required by the Company and the Bookrunners to inform themselves about, and to observe, such restrictions.
The Placing Shares to be issued pursuant to the Placing will not be admitted to trading on any stock exchange other than the
Neither the content of the Company's website nor any website accessible by hyperlinks on the Company's website is incorporated in, or forms part of, this Announcement.
This information is provided by RNS
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE